Latest Clinical News

3-Year Survival Improved with Taflinar®/Mekinist® Combination in Advanced Melanoma (07-21-2016)

Patients with advanced melanoma who were treated with the combination consisting of Taflinar (dabrafenib) plus Mekinist (trametinib) had a significantly improved survival rate at 3 years compared to those treated with Taflinar only. These results were... Continue Reading

Loxo Oncology Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for LOXO-101 (07-19-2016)

Loxo Oncology, Inc. (LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy... Continue Reading

FDA Places Hold on a Trial Evaluating Genetically Engineered Immune Cells for Cancer Treatment (07-18-2016)

The United States Food and Drug Administration (FDA) has placed a hold on a clinical trial, referred to as the ROCKET trial, due to side effects of the treatment that may be associated with 3 patient deaths. Chimeric antigen receptor (CAR) technology... Continue Reading

Niraparib Improves Progression-Free Survival in Ovarian Cancer (07-13-2016)

The PARP inhibitor niraparib improves the time to cancer progression among patients with recurrent ovarian cancer when used as maintenance therapy during platinum-based chemotherapy. Each year in the United States, approximately 22,000 women are diagnosed... Continue Reading

Syndros™ Approved for Treating Chemotherapy-Induced Nausea and Vomiting (07-12-2016)

The orally administered liquid formulation, Syndros (dronabinol), has been approved by the United States Food and Drug Administration (FDA) for the treatment of chemotherapy-induced nausea and vomiting. Syndros is an oral formulation comparable to the... Continue Reading

Imbruvica® Effective in Newly Diagnosed and Recurrent Chronic Lymphocytic Leukemia (07-11-2016)

Imbruvica (ibrutinib) produces long-lasting anti-cancer responses among patients with newly diagnosed chronic lymphocytic leukemia (CLL), as well as those who have received prior therapies. These results were recently presented at the 2016 annual meeting... Continue Reading

Darzalex™ Effective in Heavily Pre-Treated Multiple Myeloma (07-7-2016)

The targeted agent Darzalex (daratumumab) produces long-lasting anti-cancer responses among patients with multiple myeloma that has stopped responding to several prior therapies. These results were recently published in the journal Blood. Multiple myeloma... Continue Reading

Tecentriq™ Plus Abraxane® Effective Combo in Difficult to Treat Breast Cancer (06-30-2016)

The combination of the immune stimulating agent Tecentriq™ (atezolizumab), plus the chemotherapy agent Abraxane® (nab-paclitaxel) is effective in providing anti-cancer responses among patients with advanced triple-negative breast cancer (TNBC). These... Continue Reading

Novel Antibody Improves Survival in Advanced Stomach Cancer (06-28-2016)

The novel agent, IMAB362, which stimulates the immune system to attack a certain protein expressed by many stomach cancer cells, has demonstrated a significant improvement in survival compared to standard therapy among patients with this disease. These... Continue Reading

Stent Placement Reduces Need for Stoma in Some Colorectal Cancers (06-27-2016)

The placement of a stent as initial emergency treatment for colon obstruction reduces the need for a stoma without adversely affecting outcomes for patients with potentially curable colorectal cancer. These results were recently presented at the 2016... Continue Reading

Blincyto® Improves Survival in Type of Acute Lymphoblastic Leukemia (06-23-2016)

The immunotherapeutic agent, Blincyto (blinatumomab), improves survival compared to standard therapy among patients with B-cell precursor, Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (BCP-ALL) that has stopped responding to prior... Continue Reading

Directly Involving Patients Drives Participation in Metastatic Breast Cancer Study (06-22-2016)

A clinical study to accelerate research in metastatic breast cancer has rapidly enrolled participants through direct collaboration with patients. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology... Continue Reading

Next Page »